Health Trials

Waldenström's Macroglobulinemia

3

Review clinical trials related to Waldenström's Macroglobulinemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.

Participants needed: 18
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Dec 19, 2025Locations: 8
Eligibility criteria

Clinical and definitive histologic diagnosis of WM. Participant must be treatmen... [+9]

Evidence of disease transformation at the time of study entry. [+14]

Read more
Status: Recruiting

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

Participants needed: 705
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: iOMEDICO AGUpdated: Sep 23, 2025Locations: 2
Eligibility criteria

Waldenström's macroglobulinemia (all treatment lines) OR [+8]

Contraindications according to SmPC for patients with WM, CLL, MZL or FL [+1]

Read more
Status: Recruiting

R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia (Ballondor trial)

Participants needed: 54
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Kosin University Gospel HospitalUpdated: Oct 6, 2023Locations: 1
Eligibility criteria

Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia [+8]

Central nervous system involvement central nervous system (CNS) involvement by W... [+16]

Read more